| scholarly article | Q13442814 |
| P50 | author | Meindert Danhof | Q67223097 |
| P2093 | author name string | Breimer DD | |
| Urquhart J | |||
| van Brummelen P | |||
| Kleinbloesem CH | |||
| Faber H | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nifedipine | Q39111 |
| hemodynamics | Q1642137 | ||
| P304 | page(s) | 26-30 | |
| P577 | publication date | 1987-01-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans | |
| P478 | volume | 41 |
| Q72252550 | A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices |
| Q52390254 | A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. |
| Q40618142 | Advantages and disadvantages of reformulation of older drugs |
| Q71785040 | An investigation into the transdermal delivery of nifedipine |
| Q46569221 | Anticholinergic activity of 107 medications commonly used by older adults |
| Q34574831 | Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability |
| Q41272827 | Calcium channel blockers and hypertension: 2. Safety issues |
| Q41451158 | Calcium channel blockers and hypertension: evolving perspective--1996. |
| Q51553060 | Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. |
| Q34317648 | Central sympathoinhibitory effects of calcium channel blockers |
| Q41670487 | Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly |
| Q70612391 | Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers |
| Q48575604 | Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs |
| Q28367499 | Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects |
| Q46747213 | Counter-regulatory effects of combined ACE-inhibition and calcium antagonism |
| Q44523979 | Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index |
| Q54100477 | Dose adjustment of nifedipine in hypertensive patients. |
| Q51567975 | Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food. |
| Q39491108 | Early experience with dobutamine stress testing and cardiac cine-tomographic imaging in the elderly: antianginal effects of nifedipine-GITS. |
| Q41985641 | Equivalent intraperitoneal doses of ibuprofen supplemented in drinking water or in diet: a behavioral and biochemical assay using antinociceptive and thromboxane inhibitory dose-response curves in mice |
| Q35660816 | Evolving role of calcium antagonists in the management of hypertension |
| Q37945293 | Formulation approaches in enhancement of patient compliance to oral drug therapy |
| Q33750617 | Future challenges for drug delivery |
| Q40762731 | Future challenges for drug delivery research |
| Q70381328 | Haemodynamic effects of combined oral nifedipine and sublingual nitroglycerin in patients with chronic stable angina |
| Q34109300 | INTERNAL MEDICINE IN THE 21ST CENTURY: Controlled drug delivery: therapeutic and pharmacological aspects |
| Q58703159 | In vitro and in silico analysis of the effects of D receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations |
| Q40743022 | Influence of drug formulation on drug concentration-effect relationships |
| Q59710036 | Influence of input rates on (�)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers |
| Q68111027 | Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects |
| Q48232888 | Integrated TK-TD modeling for drug-induced concurrent tachycardia and QT changes in beagle dogs |
| Q33545119 | Interchangeability and predictive performance of empirical tolerance models |
| Q41400590 | Learning versus confirming in clinical drug development |
| Q81139396 | Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers |
| Q54062028 | Mibefradil: A New Selective T-Channel Calcium Antagonist for Hypertension and Angina Pectoris. |
| Q34566315 | Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris |
| Q68704398 | Negative inotropic effect of intravenous nifedipine in coronary artery disease: relation to plasma levels |
| Q69909537 | Negligible sublingual absorption of nifedipine |
| Q40923139 | Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris |
| Q43877681 | Nifedipine in Ischemic Heart Disease |
| Q39757942 | Nifedipine. Relationship between pharmacokinetics and pharmacodynamics |
| Q68466215 | Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration |
| Q40679164 | Novel oral drug formulations. Their potential in modulating adverse effects |
| Q37691861 | Optimising in vivo pharmacology studies--Practical PKPD considerations. |
| Q43222339 | Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study |
| Q45187303 | Persistence with antihypertensives related to formulation: the case of nifedipine |
| Q73850404 | Pharmacodynamic aspects of sustained release preparations |
| Q37713723 | Pharmacodynamic modelling. Application to new drug development |
| Q35922174 | Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control |
| Q40618816 | Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen |
| Q46684880 | Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs |
| Q44983998 | Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. |
| Q39513598 | Pharmacokinetics of calcium antagonists under development |
| Q37290777 | Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions |
| Q40499015 | Relevance of plasma noradrenaline concentrations to estimate autonomic effects of antihypertensive drugs |
| Q41440083 | Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm |
| Q33755752 | Role of a third generation calcium antagonist in the management of hypertension |
| Q43946781 | Serum concentration-effect relationship of (+/-)-nicardipine and nifedipine in elderly hypertensive patients |
| Q41432917 | Slowly acting calcium antagonists and their merits |
| Q36663818 | Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders |
| Q42209473 | The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction |
| Q41500150 | The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk |
| Q51745754 | The efficacy of nicardipine and nitroprusside in preventing poststernotomy hypertension. |
| Q33672006 | The efficiency concept in pharmacodynamics. |
| Q42781437 | The influence of drug input rate on the development of tolerance to frusemide |
| Q34417544 | The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. |
| Q37851883 | The management of hypertensive emergencies in children after stem cell transplantation |
| Q41143980 | The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties |
| Q69749403 | Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure |
| Q33565582 | Translating safety, efficacy and compliance into economic value for controlled release dosage forms |
| Q38204833 | Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships |
| Q41500166 | What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful? |
Search more.